Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery.
Publication/Presentation Date
1-1-2008
Abstract
Chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) can negatively impact patient quality of life, functional performance and activities of daily living. Although the development of serotonin receptor antagonists has greatly improved the control of acute emesis, delayed CINV remains a significant clinical issue. Aprepitant (Emend(®)) is the first commercially available drug from a new class of agents, the neurokinin-1 receptor antagonists. Elucidation of its mechanism of action has produced a greater understanding of the pathophysiology of nausea and vomiting. Oral aprepitant, in combination with a selective serotonin (5-HT3) receptor antagonist and corticosteroids, is indicated for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy in adults. Aprepitant alone or in combination only with dexamethasone does not optimally control acute emesis compared with triple combination therapy. By contrast, aprepitant as monotherapy is indicated for the prevention of PONV. Aprepitant represents an emerging class of agents and its addition to standard therapy provides an advanced benefit in the prevention and treatment of CINV and PONV. Investigations of aprepitant for other indications are ongoing.
Volume
1
Issue
1
First Page
27
Last Page
37
ISSN
1751-2433
Published In/Presented At
Larusso, J., Waldman, S. A., & Kraft, W. K. (2008). Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. Expert review of clinical pharmacology, 1(1), 27–37. https://doi.org/10.1586/17512433.1.1.27
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
24410507
Department(s)
Administration and Leadership
Document Type
Article